SHOWNOTES

In this episode of Telltales, Mike Nicoletti, Jason Wallace, and Hunt Lawrence unpack the latest Cash Flow Memo across energy, technology, and healthcare. The conversation ranges from Iran-driven oil risk and natural gas pricing to AI infrastructure demand, semiconductor inputs, and the long-term investment case for cancer therapies.

[00:00] Energy outlook after the Iran conflict Hunt opens with Exhibit C, explaining why he now sees oil supply tightening slightly versus prior expectations and why a return to something closer to normal in the straits could still leave a durable geopolitical risk premium in crude.

[03:24] Why oil may stay higher for longer The team discusses why WTI may average closer to $80 in 2026-2028 rather than revisiting $60, with uncertainty around Iran, damaged infrastructure, and future military escalation all influencing pricing.

[05:21] Exhibit A and the US fiscal picture Hunt argues the US remains relatively insulated on national accounts because it produces as much oil as it uses and more gas than it consumes, while still expecting the federal deficit trend to improve gradually.

[08:24] Energy equities and capital discipline The discussion turns to oil and gas names in the memo, with the view that upstream oil producers are still discounting a more conservative price deck and are unlikely to overspend even if oil averages above current expectations.

[10:09] Natural gas headwinds and LNG timing Hunt explains why higher oil production in the Permian can pressure gas prices through associated gas output, and why new LNG capacity should help eventually but may take longer to meaningfully change the price outlook.

[12:11] Helium, fertilizers, and second-order inflation effects Mike and Jason highlight other commodities affected by the conflict, including helium and fertilizers, and explain why higher input costs could ripple into semiconductors, MRI operations, and broader inflation-sensitive markets.

[13:15] Big Tech resilience and AI inference demand The hosts shift to technology, arguing that the largest platform companies remain well positioned as inference demand accelerates and hyperscalers continue building the compute capacity needed to support AI applications.

[15:10] The falling cost curve of AI Mike frames technology as fundamentally deflationary and points to the sharp drop in token costs as evidence that innovation is still rapidly compressing compute economics despite rising capital intensity.

[16:02] Google’s Turbo Quant and edge AI potential Jason explains Google’s new model architecture and why a major reduction in memory requirements could make local AI more practical, expand context windows, and move models closer to persistent memory-like functionality.

[18:15] Apple, CPUs, and the agent economy The conversation explores why Mac Mini demand may be stronger than expected and how AI agents are increasing the need for traditional CPU compute alongside GPUs.

[19:52] ARM, Intel, AMD, and the data center transition Mike and Jason discuss the shift away from x86, rising custom silicon adoption by hyperscalers, and why ARM-based architectures appear to be gaining ground in modern AI infrastructure.

[20:48] NVIDIA’s expanding role in the stack The team explains how NVIDIA has evolved from a GPU story into a full data center systems story, with process speed and integrated infrastructure now central to its ability to defend margins.

[23:02] AI meets healthcare in personalized cancer treatment Jason shares a story about a custom mRNA cancer vaccine for a dog, using it as an early proof point for how AI-assisted analysis could accelerate more personalized approaches to oncology.

[24:23] Vertex and Harrow updates The healthcare segment covers encouraging Vertex phase 3 kidney disease data and a revealing reimbursement gap at Harrow, where a low direct-to-patient price contrasts sharply with insurance billing levels.

[26:11] BioNTech after its founders The hosts debate BioNTech’s future, concluding that the company has enough late-stage assets and commercialization work ahead of it to remain viable even as the founders step back from day-to-day operating focus.

[29:50] Why cancer vaccines remain one of the biggest themes Moderna and BioNTech are highlighted as current leaders in cancer vaccines, while Jason argues the future of cancer care will likely be shaped by a combination of new therapies, better monitoring, and individualized immune-based treatment.

[31:49] The search for the next major investing themes The episode closes with a broader challenge: if AI and cancer therapies are already on the list of transformational trends, what are the other breakthroughs investors should be watching over the next three to four years?

If you enjoy this style of investing discussion, subscribe to Telltales and download the Cash Flow Memo at telltales.us. For more weekly analysis on energy, technology, healthcare, and cashflow-driven investing, stay tuned for the next episode.

This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit telltales.substack.com

From Oil Risk Premiums to Cancer Vaccines (e2613)